Investors who bought CVRx common stock between July 25, 2023 and August 6, 2026 may be covered by a proposed securities class action alleging CVRx and four current and former executives hid that Barostim sales growth depended in part on improper marketing and payment practices, the subject of a Justice Department investigation the company disclosed in August 2026. No class has been certified and there is nothing to file yet.
This article describes a class action complaint. The statements below are unproven allegations. CVRx has not been found liable, there is no certified class, and nothing to claim at this time. This page is informational and is not legal advice.
Free settlement alerts
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
The proposed class is everyone who bought CVRx common stock between July 25, 2023 and August 6, 2026, inclusive. No class has been certified yet, so the class definition can change.
CVRx disclosed that it received a civil investigative demand from the Justice Department on May 14, 2026, as part of a False Claims Act investigation into whether it improperly marketed its Barostim device, offered or paid kickbacks, or gave false information to government health insurance programs. CVRx said it was cooperating. An investigation is not a finding of wrongdoing.
Yes. Robert John, who was chief revenue officer from June 2024 until his employment ended on August 10, 2026, is one of four executives named. Some press releases have described him as CEO; the company’s filings say he was chief revenue officer.
No. The case is at the complaint stage. There is no settlement and no claim form. The January 8, 2027 date is the deadline to ask to be lead plaintiff, not a claim deadline.